Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

Inclusion Criteria: Cognitively Healthy Volunteers * Mini-mental state examination (MMSE) ≥ 28 * No history of cognitive decline or parkinsonian motor disorder CBD and PSP subjects * Able to walk 10 steps with minimal assistance * MMSE ≥ 14 and ≤ 30 * Subject has a reliable study partner who agrees to accompany subject to visits and spends at least 5 hours per week with the subject PSP subjects only * Meet National Institute of Neurological Disorders and Stroke - Society for Progressive Supranuclear Palsy (NINDS-SPSP) probable or possible PSP criteria as modified for the Neuroprotection and Natural History Parkinson Plus Syndromes (NNIPPS) clinical trial CBD subjects only * Meets 2013 consensus criteria for possible or probable corticobasal degeneration, corticobasal syndrome (CBS) subtype Exclusion Criteria: All subjects * Have evidence of structural abnormalities such as vascular disease, large strokes or severe white matter disease or other mass lesion on screening MRI * Claustrophobia * Current clinically significant cardiovascular disease or clinically significant abnormalities on screening electrocardiogram (e.g. corrected QT interval \>450 msec) * Have a history of risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of long QT syndrome) * Have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer * Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception * Have received or participated in a trial with investigational medications in the past 30 days * Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session * Have a history of neuroleptic use for a prolonged period of time or within the past 6 months PSP and CBD subjects * Have evidence of amyloid deposition * Meet National Institute on Aging-Alzheimer's Association criteria for probable Alzheimer's Disease * Have any other neurological condition other than CBS or PSP that could account for cognitive or motor deficits * Serum or plasma progranulin level less than one standard deviation below the normal subject mean for the laboratory performing the assay * Have a high-risk family history suggestive of tar DNA binding protein (TDP)-43 pathology or known mutations